| Name | e-Therapeutics |
|---|---|
| Epic | ETX |
| Isin | GB00B2823H99 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 9.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £52.59 | Debt ratio | n/a |
| Shares in issue | 584.34 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -30.93 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.54 | 52-week high / low | 8.13p / 23.10p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | e-Therapeutics |
|---|---|
| Address | 17 Blenheim Office Park, Long Hanborough, United Kingdom, OX29 8LN |
| Telephone | +44 (0) 191 233 1317 |
| Website | http://www.etherapeutics.co.uk/ |
| Director | Position |
|---|---|
| Mr Ali Mortazavi | CEO |
| Mr Trevor Mervyn Jones | Chairman |
| Mr Michael Anthony Bretherton | Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/01/23 | 31/01/22 | 31/01/21 |
| Intangible asssets and goodwill | 0.24 | 0.1 | 0.08 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.64 | 0.91 | 0.16 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 2.31 | 2.21 | 1.12 |
| Cash and equivalents | 31.69 | 11.35 | 7 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 34.64 | 29.52 | 14.31 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 1.6 | 1.49 | 0.43 |
| Long term liabilities | n/a | 0.29 | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1.6 | 1.79 | 0.43 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 33.04 | 27.73 | 13.88 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.58 | 0.52 | 0.42 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -80.15 | -72.03 | -64.2 |
| Share premium account | 112.61 | 99.24 | 77.67 |
| Total equity | 33.04 | 27.73 | 13.88 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -10.24 | -9.57 | -4.49 |
| Pre-tax profit | -9.77 | -9.52 | -4.47 |